About: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 March 2002

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в березні 2002 (uk) im März 2002 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en marzu de 2002 (ast) scientific article published on 01 March 2002 (en)
publication date	wds:Q77836261-7651B92D-255B-4652-AE36-6DCBD4E49F50
publication date	2002-03-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q77836261-728302BC-F7F9-4112-80B2-54EE99739812
language of work or name	English
author name string	wds:Q77836261-03844C5C-232E-44BE-BB4B-3FE8116A8B53 wds:Q77836261-174ADB3F-7366-4D58-BCDF-C084455A3B68 wds:Q77836261-57195271-ED63-44D3-B8C3-C386BBB0C8FC wds:Q77836261-68B169F9-6A0E-4A8C-987E-F563C7C703D2 wds:Q77836261-92232A2C-238E-4542-A4D7-1239D765DCD3 wds:Q77836261-961E8FF3-7C93-4BFB-BFD6-827B3EA8F25B wds:Q77836261-9928906B-A496-4B58-974C-76AFD703E989 wds:Q77836261-A78CA67F-95D3-4E45-956A-02854AA7DEF8 wds:Q77836261-AF12D4E0-E16B-44B7-A32F-ECB022519DC8 wds:Q77836261-C7921E08-1CE7-4AA7-9C0C-91069916BCCB wds:Q77836261-DFCA82C2-518E-412A-9FFF-3C3D74630557
author name string	Alexandra J Lansky Cindy L Grines David A Cox Eulogio Garcia James E Tcheng John D Carroll John J Griffin Mark Turco Thomas Stuckey Giulio Guagliumi Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators
rdfs:label	Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction (en) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction (nl)
skos:prefLabel	Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction (en) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction (nl)
name	Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction (en) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction (nl)
author	wds:Q77836261-12EF1BA8-98E8-460F-BCFF-BEC8FA6C3DF7 wds:Q77836261-78218CA6-21BC-46C8-85FF-D9BF874A8145
author	Gregg W Stone Barry Rutherford
title	wds:Q77836261-AB1A9D11-FBFC-4A9E-9840-D8940516AB0C
title	Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction (en)
page(s)	wds:Q77836261-DA9484DE-F8EC-4B33-A7CC-0178C0535F1D
page(s)	957-966
instance of	wds:Q77836261-58220E57-380F-4F7D-AEBD-7A60A288B749
instance of	scholarly article
main subject	wds:Q77836261-1103D253-0E04-43F9-81BD-5A6F397F26BF wds:Q77836261-D5C9E2DA-E0C5-42B4-AF2A-BB40A83D47EF
main subject	angioplasty acute myocardial infarction
PubMed ID	wds:Q77836261-A3A9DEC2-0032-4851-B0F3-E9C98FB9BEB9
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/11919304
PubMed ID	11919304
published in	wds:Q77836261-39296AE5-281A-45FC-AB62-593F36DCA8BA
published in	The New England Journal of Medicine
issue	wds:Q77836261-82189D4E-94E1-41C7-88B4-DF06E57F4FBA
volume	wds:Q77836261-5BE728BB-9372-4FBA-849A-F3354E7176FA
issue	13
volume	346
DOI	wds:Q77836261-13A71966-2B4C-4E25-93D4-DC62C31509D6
DOI	http://dx.doi.org/10.1056/NEJMOA013404
DOI	10.1056/NEJMOA013404
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q77836261
is cites work of	Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary Value of T2-weighted, first-pass and delayed enhancement, and cine CMR to differentiate between acute and chronic myocardial infarction Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: Acute myocardial infarction Nitric oxide, platelet function, myocardial infarction and reperfusion therapies Two-Year Follow-up of Sirolimus-Eluting Stents versus Paclitaxel-Eluting Stents in Acute Myocardial Infarction Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial Acute coronary syndrome: ST segment elevation myocardial infarction Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in? Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions Intracoronary thrombectomy improves myocardial reperfusion in patients undergoing direct angioplasty for acute myocardial infarction Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Lei Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial Distal protection in native coronary arteries during primary angioplasty in acute myocardial infarction: Single‐center experience Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial Percutaneous coronary intervention: recommendations for good practice and training Long-term effects of autologous bone marrow stem cell treatment in acute myocardial infarction: factors that may influence outcomes Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial Statin therapy and mortalitiy in patients with ST-segment elevation myocardial infarction treated with primary angioplasty 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. The evolution of antiplatelet therapy in cardiovascular disease Excimer laser in myocardial infarction: a comparison between STEMI patients with established Q-wave versus patients with non-STEMI (non-Q). Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention The causal role of megakaryocyte–platelet hyperactivity in acute coronary syndromes. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software